Eupraxia PharmaceuticalsTSX:EPRX +2.85%37 Quick Ratio is 19.30 as of Mar. 2026, which is 139% above its 10-year median of 8.07. GuruFocus rates TSX:EPRX with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 1,412 Biotechnology companies, Eupraxia Pharmaceuticals ranks better than 91.64% on this metric.
Eupraxia Pharmaceuticals has a quick ratio of 19.30. It generally indicates good short-term financial strength.
The historical rank and industry rank for Eupraxia Pharmaceuticals's Quick Ratio or its related term are showing as below:
TSX:EPRX'
s Quick Ratio Range Over the Past 10 Years
Min: 0.03 Med: 8.07 Max: 45.19
Current: 19.3
During the past 9 years, Eupraxia Pharmaceuticals's highest Quick Ratio was 45.19. The lowest was 0.03. And the median was 8.07.
TSX:EPRX's Quick Ratio is ranked better than 91.64% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs TSX:EPRX: 19.30
Eupraxia Pharmaceuticals (TSX:EPRX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Eupraxia Pharmaceuticals Quick Ratio Related Terms
Eupraxia Pharmaceuticals Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSX:EPRX vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Eupraxia Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eupraxia Pharmaceuticals Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Eupraxia Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Eupraxia Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Eupraxia Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eupraxia Pharmaceuticals (TSX:EPRX) has a Quick Ratio of 19.30 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Eupraxia Pharmaceuticals and its competitors. This is 139% above median its historical median of 8.07. Over the past decade, Eupraxia Pharmaceuticals' Quick Ratio has ranged from 0.03 to 45.19. According to the industry distribution chart, Eupraxia Pharmaceuticals ranks #118 out of 1412 companies in the Biotechnology industry, placing it in the top 8.4%.
Is Eupraxia Pharmaceuticals' Quick Ratio too high?
Eupraxia Pharmaceuticals' current Quick Ratio of 19.30 is 139% above median its 10-year median of 8.07. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 45.19. The Biotechnology industry median Quick Ratio is 3.60. Eupraxia Pharmaceuticals' value of 19.30 is 436.1% above this industry median. Based on the distribution chart, Eupraxia Pharmaceuticals ranks #118 out of 1412 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Eupraxia Pharmaceuticals has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Eupraxia Pharmaceuticals' Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Eupraxia Pharmaceuticals ranks #118 out of 1412 companies for Quick Ratio. This places Eupraxia Pharmaceuticals in the top 8% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Eupraxia Pharmaceuticals' value of 19.30 is 436.1% above this benchmark. Historically, Eupraxia Pharmaceuticals' own Quick Ratio has ranged from 0.03 to 45.19 over the past decade. While the company's 10-year median is 8.07 vs. the industry median of 3.60, Eupraxia Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eupraxia Pharmaceuticals's current Quick Ratio of 19.30 is 436.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Eupraxia Pharmaceuticals and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eupraxia Pharmaceuticals's current Quick Ratio is 19.30, which is 139% above median its own 10-year median of 8.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eupraxia Pharmaceuticals stock overvalued right now?
Eupraxia Pharmaceuticals (TSX:EPRX) has a current Quick Ratio of 19.30. The current Quick Ratio is 19.30, which is 139% above median its 10-year median of 8.07 and 436.1% above the Biotechnology industry median of 3.60. Eupraxia Pharmaceuticals' overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Eupraxia Pharmaceuticals (TSX:EPRX), the current Quick Ratio is 19.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
37GF Score
Get the complete analysis for TSX:EPRX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:EPRX has been successfully added to your 
